Cochrane for Clinicians
Putting Evidence into Practice
Antiretroviral Preexposure Prophylaxis for Preventing HIV Infection in High-Risk Individuals
Am Fam Physician. 2013 Aug 1;88(3):172-173.
Author disclosure: No relevant financial affiliations.
Does antiretroviral preexposure prophylaxis reduce the risk of contracting human immunodeficiency virus (HIV) infection in high-risk individuals?
For some groups of patients at greater risk of HIV infection (e.g., serodiscordant partners, men who have sex with men and engage in high-risk behaviors, persons with multiple concurrent sex partners, persons who exchange sex for money), preexposure prophylaxis decreased the risk of acquiring HIV infection (number needed to treat [NNT] = 56). (Strength of Recommendation: C, based on consensus, disease-oriented evidence, usual practice, expert opinion, or case series.)
In 2011, there were 34 million persons living with HIV infection and 1.7 million AIDS-related deaths around the world.1 The burden of disease falls disproportionately on residents of sub-Saharan Africa, who comprise approximately two-thirds of all persons who are HIV positive.2 Current efforts to prevent the spread of HIV involve surveillance programs, health communications strategies, efforts to reduce the rates of unprotected sex, needle exchange services, antiretroviral treatment, and vertical transmission prophylaxis.3 A promising additional method to prevent the spread of HIV infection involves preexposure prophylaxis.
This Cochrane review investigated the effects of preexposure prophylaxis in six randomized controlled trials involving 12,945 participants from the United States, South America, Southeast Asia, and Africa. Participants were given the reverse transcriptase inhibitor tenofovir (300 mg) or tenofovir/emtricitabine (Truvada; 300/200 mg), or placebo daily. At baseline, participants had to be HIV negative and fall into at least one high-risk category.
In four studies (n = 8,918) comparing tenofovir/emtricitabine with placebo, patients in the intervention arm had a risk ratio of 0.51 (95% confidence interval [CI], 0.30 to 0.85) for contracting HIV. In two studies (n = 4,027) comparing tenofovir with placebo, patients in the intervention arm had a risk ratio of 0.38 (95% CI, 0.23 to 0.63) for becoming infected. The absolute risk reduction in the tenofovir/emtricitabine arm was 1.8% (NNT to prevent one infection = 56). In the tenofovir-only arm, the absolute risk reduction was 1.6% (NNT = 61). There were no differences in preventive effectiveness between males and females, nor was there a benefit of tenofovir/emtricitabine over tenofovir alone. Although study participants in the intervention and placebo groups reported high levels of adherence, two studies demonstrated lower detectable drug levels among those in the intervention arm who contracted HIV infection. Rates of serious adverse effects were similar among all groups (risk ratio = 1.00; 95% CI, 0.83 to 1.19). Changes in viral resistance patterns, a potential concern of widespread preexposure prophylaxis use, were not assessed.
The U.S. Food and Drug Administration has approved the combination of tenofovir/emtricitabine for preexposure prophylaxis in persons at high risk of contracting HIV. Based on its own review of the evidence, the Centers for Disease Control and Prevention (CDC) has offered guidance on which individuals to consider for preexposure prophylaxis: men who have sex with men and engage in high-risk behaviors (e.g., multiple partners in an HIV-endemic area, frequent partner changes) and heterosexual individuals in a serodiscordant relationship.4,5 Another group to consider based on this review is heterosexual persons with multiple partners, including those working in the sex trade. The use of HIV preexposure prophylaxis is not universally accepted because of concerns about poor medication adherence and the potential development of resistance. In its guidance, the CDC stresses that preexposure prophylaxis should be part of a comprehensive program that includes safer-sex counseling, condom distribution, education, testing, and other established strategies to reduce the risk of HIV transmission.4,5
SOURCE: Okwundu CI, Uthman OA, Okoromah CA. Anti-retroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev. 2012;7:CD007189.
The practice recommendations in this activity are available at http://summaries.cochrane.org/CD007189.
REFERENCESshow all references
1. World Health Organization. Global summary of the HIV/AIDS epidemic, December 2011. http://www.who.int/hiv/data/. Accessed June 8, 2013....
2. Joint United Nations Programme on HIV/AIDS (UNAIDS), World Health Organization (WHO). AIDS epidemic update: November 2009. http://www.unaids.org/en/media/unaids/contentassets/dataimport/pub/report/2009/jc1700_epi_update_2009_en.pdf. Accessed November 12, 2012.
3. World Health Organization. HIV in the WHO African Region: progress towards achieving universal access to priority health sector interventions, 2011 update. http://www.afro.who.int/en/clusters-a-programmes/dpc/acquired-immune-deficiency-syndrome/features/3015-hiv-in-the-who-african-region-progress-towards-achieving-universal-access-to-priority-health-sector-interventions-2011-update.html. Accessed November 12, 2012.
4. CDC. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR Morb Mortal Wkly Rep. 2011;60(3):65–68.
5. CDC. Interim guidance for clinicians considering the use of preexposure prophylaxis for the prevention of HIV infection in heterosexually active adults. MMWR Morb Mortal Wkly Rep. 2012;61(31):586–589.
These are summaries of reviews from the Cochrane Library.
The series coordinator for AFP is Corey D. Fogleman, MD, Lancaster General Hospital Family Medicine Residency, Lancaster, Pa.
A collection of Cochrane for Clinicians published in AFP is available at https://www.aafp.org/afp/cochrane.
Copyright © 2013 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact email@example.com for copyright questions and/or permission requests.
Want to use this article elsewhere? Get Permissions
More in AFP
MOST RECENT ISSUE
Sep 15, 2019
Access the latest issue of American Family Physician